[1]徐冉冉.2019-2020年我院耐碳青霉烯类铜绿假单胞菌的耐药性及临床特征分析[J].医学信息,2021,34(20):158-160.[doi:10.3969/j.issn.1006-1959.2021.20.042]
　XU Ran-ran.Drug Resistance and Clinical Characteristics of Carbapenem-resistant Pseudomonas Aeruginosa in Our Hospital from 2019 to 2020[J].Medical Information,2021,34(20):158-160.[doi:10.3969/j.issn.1006-1959.2021.20.042]
点击复制

2019-2020年我院耐碳青霉烯类铜绿假单胞菌的耐药性及临床特征分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年20期
页码:
158-160
栏目:
调查分析
出版日期:
2021-10-20

文章信息/Info

Title:
Drug Resistance and Clinical Characteristics of Carbapenem-resistant Pseudomonas Aeruginosa in Our Hospital from 2019 to 2020
文章编号:
1006-1959（2021）20-0158-03
作者:
徐冉冉
如东县中医院检验科，江苏 如东 226400
Author(s):
XU Ran-ran
Department of Laboratory,Rudong Hospital of Traditional Chinese Medicine,Rudong 226400,Jiangsu,China
关键词:
耐碳青霉烯类; 铜绿假单胞菌; 耐药性
Keywords:
Carbapenem resistance; Pseudomonas aeruginosa; Drug resistance
分类号:
R378.991
DOI:
10.3969/j.issn.1006-1959.2021.20.042
文献标志码:
A
摘要:
目的 分析2019-2020年如东县中医院耐碳青霉烯类铜绿假单胞菌的耐药性及临床特征。方法 回顾性分析如东县中医院2019年10月-2020年10月分离的150株铜绿假单胞菌（PEA），统计耐碳青霉烯类铜绿假单胞菌（CRPA）检出情况以及分布情况，比较CRPA与非CRPA耐药性及临床特征，并分析CRPA发生的独立危险因素。结果 150株PAE中CRPA共40株，占比26.67%，以痰标本为主，且主要分布于重症医学科。CRPA与非CRPA头孢哌酮/舒巴坦耐药性比较，差异无统计学意义（P＞0.05）；其他药物CRPA与非CRPA耐药性比较，差异有统计学意义（P＜0.05）。CRPA与非CRPA年龄、入住ICU时间、住院时间、机械通气、留置管、经验性使用光谱抗菌药物比较，差异有统计学意义（P＜0.05）；CRPA与非CRPA性别、经验性使用抗菌药物比较，差异无统计学意义（P＞0.05）。Logistic回归分析显示，年龄、入住ICU时间、机械通气、留置管以及经验性使用广谱抗菌药物是导致CRPA的独立危险因素。结论 临床治疗CRPA患者应以阿米卡星、妥布霉素、β-内酰胺类抗菌药物等为主，保证抗感染治疗的有效性。同时，应当明确CRPA发生的危险因素，采取针对性的预防措施，从而降低CRPA感染，避免耐药株的播散与流行。
Abstract:
Objective To analyze the drug resistance and clinical characteristics of carbapenem-resistant Pseudomonas aeruginosa in Rudong Hospital of Traditional Chinese Medicine from 2019 to 2020.Methods A total of 150 strains of Pseudomonas aeruginosa (PAE) isolated from Rudong Hospital of Traditional Chinese Medicine from October 2019 to October 2020 were retrospectively analyzed. The detection and distribution of carbapenem-resistant Pseudomonas aeruginosa (CRPA) were statistically analyzed. The drug resistance and clinical characteristics of CRPA and non-CRPA were compared, and the independent risk factors of CRPA were analyzed.Results Among 150 strains of PAE, 40 strains were CRPA, accounting for 26.67%, mainly sputum specimens, and mainly distributed in the Department of Critical Care Medicine. There was no statistically significant difference in the resistance of cefoperazone/sulbactam between CRPA and non-CRPA (P>0.05)， while there were statistically significant difference in other drug resistance between CRPA and non-CRPA (P<0.05). There were statistically significant differences in age, length of stay in ICU, hospitalization time, mechanical ventilation, indwelling catheter, and empirical use of antibiotics between CRPA and non-CRPA (P<0.05), while there were no statistically significant difference in gender, empirical use of antibacterial drugs between CRPA and non-CRPA (P>0.05). Logistic regression analysis showed that age, length of stay in ICU, mechanical ventilation, indwelling tube, and empirical use of broad-spectrum antibiotics were independent risk factors for CRPA.Conclusion Clinical treatment of CRPA patients should be amikacin, tobramycin, and β-lactam antibiotics as the mainstay to ensure the effectiveness of anti-infective treatment. At the same time, the risk factors of CRPA should be clarified, and targeted preventive measures should be taken to reduce CRPA infection and avoid the spread and epidemic of drug-resistant strains.

参考文献/References:

[1]李东明,王宇凡,武玉晶,等.耐碳青霉烯革兰阴性杆菌耐药性及基因分型[J].中华医院感染学杂志,2021,31(6):816-820.[2]刘刚,魏莲花,邹凤梅,等.2011-2016年耐碳青霉烯类抗菌药物肠杆菌科细菌的分布特点和耐药性分析[J].中国医药科学,2018,8(9):20-23.[3]Karampatakis T,Antachopoulos C,Tsakris A,et al.Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data[J].Eur J Clin Microbiol Infect Dis,2018,37(7):1211-1220.[4]李飞,李丽娟,梁德志,等.耐亚胺培南铜绿假单胞菌耐药特征及其耐药机制的研究[J].分子诊断与治疗杂志,2019,11(2):101-106,140.[5]陈约慧,应芙蓉,詹玲玲,等.1543株铜绿假单胞菌感染的临床分布与耐药性分析[J].中国临床药理学杂志,2018,34(24):2814-2817.[6]Chew KL,Octavia S,Ng OT,et al.Challenge of drug resistance in Pseudomonas aeruginosa: clonal spread of NDM-1-positive ST-308 within a tertiary hospital[J].J Antimicrob Chemother,2019,74(8):2220-2224.[7]袁莉莉,丁百兴,沈震,等.耐碳青霉烯类铜绿假单胞菌的耐药性及分子流行病学研究[J].中国感染与化疗杂志,2017,17(3):289-292.[8]袁莉莉,丁百兴,沈震,等.碳青霉烯类抗生素耐药铜绿假单胞菌感染的临床研究[J].中国感染与化疗杂志,2017,17(2):121-126.[9]Gill JS,Arora S,Khanna SP,et al.Prevalence of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa from a Tertiary Level Intensive Care Unit[J].J Glob Infect Dis,2016,8(4):155-159.[10]司忠花,董玉俊,李玉.基层医院铜绿假单胞菌耐药性分析及耐药基因检测[J].中华医院感染学杂志,2017,27(1):43-46.[11]李婷婷,韩冠英.某院铜绿假单胞菌耐药性与抗菌药物使用量的相关性分析[J].中国医院药学杂志,2016,36(19):1689-1693.[12]Fernandes M,Vira D,Medikonda R,et al.Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome[J].Graefes Arch Clin Exp Ophthalmol,2016,254(2):315-322.[13]曾为伦,吴海鸥,章如玲,等.多重耐药铜绿假单胞菌的相关耐药机制研究[J].中国抗生素杂志,2016,41(5):377-381.[14]Jayanthi G,Sharif M.Phenotypic and Molecular Characterization of Clinical isolates of Drug Resistant Pseudomonas aeruginosa[J].Current Therapeutic Research,2016,65(5):423-432.[15]张祎博,孙景勇,倪语星,等.2005-2014年CHINET铜绿假单胞菌耐药性监测[J].中国感染与化疗杂志,2016,16(2):141-145.

相似文献/References:

[1]李绪定.碳青霉烯类治疗铜绿假单胞菌肺炎的临床效果分析[J].医学信息,2018,31(13):134.[doi:10.3969/j.issn.1006-1959.2018.13.039]
　LI Xu-ding.Clinical Effect of Carbapenem in the Treatment of Pseudomonas Aeruginosa Pneumonia[J].Medical Information,2018,31(20):134.[doi:10.3969/j.issn.1006-1959.2018.13.039]
[2]王永宁,王瑞文,薛 郡,等.天津地区某基层医院铜绿假单胞菌的5年耐药变迁[J].医学信息,2019,32(09):124.[doi:10.3969/j.issn.1006-1959.2019.09.041]
　WANG Yong-ning,WANG Rui-wen,XUE Jun,et al.Five-year Resistance Change of Pseudomonas Aeruginosa in a Primary Hospital in Tianjin[J].Medical Information,2019,32(20):124.[doi:10.3969/j.issn.1006-1959.2019.09.041]
[3]王春梅,闫琳琳,谷依林,等.北京西部地区某医院铜绿假单胞菌的临床分布及耐药性分析[J].医学信息,2021,34(01):145.[doi:10.3969/j.issn.1006-1959.2021.01.039]
　WANG Chun-mei,YAN Lin-lin,GU Yi-lin,et al.Clinical Distribution and Drug Resistance Analysis of Pseudomonas Aeruginosa in a Hospital in Western Beijing[J].Medical Information,2021,34(20):145.[doi:10.3969/j.issn.1006-1959.2021.01.039]
[4]游六勇,罗文英.铜绿假单胞菌生物膜干预治疗的研究[J].医学信息,2022,35(06):37.[doi:10.3969/j.issn.1006-1959.2022.06.009]
　YOU Liu-yong,LUO Wen-ying.Research on Pseudomonas Aeruginosa Biofilm Interventions for Governance[J].Medical Information,2022,35(20):37.[doi:10.3969/j.issn.1006-1959.2022.06.009]

更新日期/Last Update: 1900-01-01